

Reijo Laaksonen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2341063/publications.pdf>

Version: 2024-02-01

54
papers

2,959
citations

257450

24
h-index

168389

53
g-index

54
all docs

54
docs citations

54
times ranked

5443
citing authors

#	ARTICLE	IF	CITATIONS
1	Primary cardiovascular risk prediction by LDL-cholesterol in Caucasian middle-aged and older adults: a joint analysis of three cohorts. <i>European Journal of Preventive Cardiology</i> , 2022, 29, e128-e137.	1.8	9
2	Comparison of recent ceramide-based coronary risk prediction scores in cardiovascular disease patients. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 947-956.	1.8	10
3	TNF α induces endothelial dysfunction in rheumatoid arthritis via LOX-1 and arginase 2: reversal by monoclonal TNF α antibodies. <i>Cardiovascular Research</i> , 2022, 118, 254-266.	3.8	13
4	Plasma ceramide and phospholipid-based risk score and the risk of cardiovascular death in patients after acute coronary syndrome. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 895-902.	1.8	18
5	Ceramides and phospholipids in plasma extracellular vesicles are associated with high risk of major cardiovascular events after carotid endarterectomy. <i>Scientific Reports</i> , 2022, 12, 5521.	3.3	8
6	Plasma ceramides independently predict all-cause mortality in men aged 85+. <i>Age and Ageing</i> , 2022, 51, .	1.6	1
7	Improving 1-year mortality prediction in ACS patients using machine learning. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 855-865.	1.0	9
8	Absolute and relative risk prediction in cardiovascular primary prevention with a modified SCORE chart incorporating ceramide-phospholipid risk score and diabetes mellitus. <i>European Heart Journal Open</i> , 2021, 1, .	2.3	11
9	Trimethyllysine predicts all-cause and cardiovascular mortality in community-dwelling adults and patients with coronary heart disease. <i>European Heart Journal Open</i> , 2021, 1, .	2.3	4
10	Prior myocardial infarction, coronary artery disease extent, diabetes mellitus, and CERT2 score for risk stratification in stable coronary artery disease. <i>European Journal of Preventive Cardiology</i> , 2021, , .	1.8	5
11	Coffee, Atrial Fibrillation, and Circulating Ceramides in Patients with Chronic Heart Failure. <i>Journal of Agricultural and Food Chemistry</i> , 2021, 69, 11236-11245.	5.2	5
12	A Randomized Controlled Dietary Intervention Improved the Serum Lipid Signature towards a Less Atherogenic Profile in Patients with Rheumatoid Arthritis. <i>Metabolites</i> , 2021, 11, 632.	2.9	6
13	Uncovering the shared lipidomic markers of subclinical osteoporosis-atherosclerosis comorbidity: The Young Finns Study. <i>Bone</i> , 2021, 151, 116030.	2.9	13
14	Development and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients. <i>European Heart Journal</i> , 2020, 41, 371-380.	2.2	180
15	Fenretinide treatment accelerates atherosclerosis development in apoE α -deficient mice in spite of beneficial metabolic effects. <i>British Journal of Pharmacology</i> , 2020, 177, 328-345.	5.4	21
16	Lipidomic architecture shared by subclinical markers of osteoporosis and atherosclerosis: The Cardiovascular Risk in Young Finns Study. <i>Bone</i> , 2020, 131, 115160.	2.9	20
17	Ceramides and Ceramide Scores: Clinical Applications for Cardiometabolic Risk Stratification. <i>Frontiers in Endocrinology</i> , 2020, 11, 570628.	3.5	65
18	Ceramides improve atherosclerotic cardiovascular disease risk assessment beyond standard risk factors. <i>Clinica Chimica Acta</i> , 2020, 511, 138-142.	1.1	25

#	ARTICLE	IF	CITATIONS
19	Prediction of Residual Risk by Ceramide-Phospholipid Score in Patients With Stable Coronary Heart Disease on Optimal Medical Therapy. <i>Journal of the American Heart Association</i> , 2020, 9, e015258.	3.7	34
20	Sex-specific associations of TCF7L2 variants with fasting glucose, type 2 diabetes and coronary heart disease among Turkish adults. <i>Anatolian Journal of Cardiology</i> , 2020, 24, 326-333.	0.9	1
21	hiPSC-derived hepatocytes closely mimic the lipid profile of primary hepatocytes: A future personalised cell model for studying the lipid metabolism of the liver. <i>Journal of Cellular Physiology</i> , 2019, 234, 3744-3761.	4.1	16
22	New evidence from plasma ceramides links apoE polymorphism to greater risk of coronary artery disease in Finnish adults. <i>Journal of Lipid Research</i> , 2019, 60, 1622-1629.	4.2	27
23	LDL triglycerides, hepatic lipase activity, and coronary artery disease: An epidemiologic and Mendelian randomization study. <i>Atherosclerosis</i> , 2019, 282, 37-44.	0.8	38
24	Whole blood microRNA levels associate with glycemic status and correlate with target mRNAs in pathways important to type 2 diabetes. <i>Scientific Reports</i> , 2019, 9, 8887.	3.3	55
25	Dedifferentiation of Primary Hepatocytes is Accompanied with Reorganization of Lipid Metabolism Indicated by Altered Molecular Lipid and miRNA Profiles. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2910.	4.1	21
26	PCSK9 inhibition alters the lipidome of plasma and lipoprotein fractions. <i>Atherosclerosis</i> , 2018, 269, 159-165.	0.8	56
27	Association of Plasma Ceramides With Myocardial Perfusion in Patients With Coronary Artery Disease Undergoing Stress Myocardial Perfusion Scintigraphy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 2854-2861.	2.4	29
28	Plasma concentrations of molecular lipid species predict long-term clinical outcome in coronary artery disease patients. <i>Journal of Lipid Research</i> , 2018, 59, 1729-1737.	4.2	105
29	Susceptibility of low-density lipoprotein particles to aggregate depends on particle lipidome, is modifiable, and associates with future cardiovascular deaths. <i>European Heart Journal</i> , 2018, 39, 2562-2573.	2.2	126
30	Differentially expressed genes and canonical pathway expression in human atherosclerotic plaques – Tampere Vascular Study. <i>Scientific Reports</i> , 2017, 7, 41483.	3.3	52
31	Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 534-543.	11.4	84
32	Differentially expressed genes and canonical pathways in the ascending thoracic aortic aneurysm – The Tampere Vascular Study. <i>Scientific Reports</i> , 2017, 7, 12127.	3.3	20
33	Associations of functional alanine-glyoxylate aminotransferase 2 gene variants with atrial fibrillation and ischemic stroke. <i>Scientific Reports</i> , 2016, 6, 23207.	3.3	20
34	Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol. <i>European Heart Journal</i> , 2016, 37, 1967-1976.	2.2	433
35	Circulating Ceramides Predict Cardiovascular Outcomes in the Population-Based FINRISK 2002 Cohort. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 2424-2430.	2.4	249
36	Fast and Accurate Construction of Confidence Intervals for Heritability. <i>American Journal of Human Genetics</i> , 2016, 98, 1181-1192.	6.2	31

#	ARTICLE	IF	CITATIONS
37	Development and validation of a high-throughput LC-MS/MS assay for routine measurement of molecular ceramides. <i>Analytical and Bioanalytical Chemistry</i> , 2016, 408, 3475-3483.	3.7	61
38	Fish oil and krill oil differentially modify the liver and brain lipidome when fed to mice. <i>Lipids in Health and Disease</i> , 2015, 14, 88.	3.0	24
39	Differential Network Analysis with Multiply Imputed Lipidomic Data. <i>PLoS ONE</i> , 2015, 10, e0121449.	2.5	3
40	Plasma concentrations of molecular lipid species in relation to coronary plaque characteristics and cardiovascular outcome: Results of the ATHEROREMO-IVUS study. <i>Atherosclerosis</i> , 2015, 243, 560-566.	0.8	120
41	Kindlin 3 (FERMT3) is associated with unstable atherosclerotic plaques, anti-inflammatory type II macrophages and upregulation of beta-2 integrins in all major arterial beds. <i>Atherosclerosis</i> , 2015, 242, 145-154.	0.8	29
42	Genetic variants primarily associated with type 2 diabetes are related to coronary artery disease risk. <i>Atherosclerosis</i> , 2015, 241, 419-426.	0.8	26
43	Predicting sudden cardiac death using common genetic risk variants for coronary artery disease. <i>European Heart Journal</i> , 2015, 36, 1669-1675.	2.2	26
44	Use and role of monoclonal antibodies and other biologics in preventive cardiology. <i>Swiss Medical Weekly</i> , 2015, 145, w14179.	1.6	3
45	Integrative Genomics Reveals Novel Molecular Pathways and Gene Networks for Coronary Artery Disease. <i>PLoS Genetics</i> , 2014, 10, e1004502.	3.5	192
46	EPIQ—efficient detection of SNP-SNP epistatic interactions for quantitative traits. <i>Bioinformatics</i> , 2014, 30, i19-i25.	4.1	11
47	Blood microRNA profile associates with the levels of serum lipids and metabolites associated with glucose metabolism and insulin resistance and pinpoints pathways underlying metabolic syndrome. <i>Molecular and Cellular Endocrinology</i> , 2014, 391, 41-49.	3.2	65
48	Molecular Lipids Identify Cardiovascular Risk and Are Efficiently Lowered by Simvastatin and PCSK9 Deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E45-E52.	3.6	180
49	Shared Genetic Susceptibility to Ischemic Stroke and Coronary Artery Disease. <i>Stroke</i> , 2014, 45, 24-36.	2.0	302
50	Abnormal Splicing of NEDD4 in Myotonic Dystrophy Type 2. <i>American Journal of Pathology</i> , 2014, 184, 2322-2332.	3.8	16
51	STOMPing forward: Statins, muscle complaints and CK. <i>Atherosclerosis</i> , 2013, 230, 256-257.	0.8	6
52	Lipidomics-Based Safety Biomarkers for Lipid-Lowering Treatments. <i>Angiology</i> , 2008, 59, 65S-68S.	1.8	23
53	On the mechanisms of statin-induced myopathy. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 79, 529-531.	4.7	28
54	Paraoxonase gene polymorphisms and coronary reactivity in young healthy men. <i>Journal of Molecular Medicine</i> , 2001, 79, 449-456.	3.9	24